Products Categories
    Product Certification&
    Enterprise Certification

    shanxiyuhong

    Country: Country China (Mainland)

    Business Type: Trading Company

    Enterprise Authentication

  • Mr.zhang
    Tel: 15694893258

  • Mobile:
  • Tel:15694893258
  • Fax:
  • URL:http://
  • Province/state:shanxi
  • City:taiyuan
  • Street:International Building,Haitang,68 Jinyang street,Xiaodian District,Taiyuan
  • MaxCard:
Home > Products >  Sex Enhancement Powder Flibanserin cas:167933-07-5

Sex Enhancement Powder Flibanserin cas:167933-07-5 CAS NO.167933-07-5

  • Min.Order: 1 Kilogram
  • Payment Terms: T/T,
  • Product Details

Keywords

  • Flibanserin
  • Flibanserin
  • steroid

Quick Details

  • ProName: Sex Enhancement Powder Flibanserin cas...
  • CasNo: 167933-07-5
  • Molecular Formula: C9H11NO2
  • Appearance: white powder
  • Application: Used in Synthesis, Pharmaceuticals
  • DeliveryTime: within 7 days
  • PackAge: bag or carton
  • Port: xingang
  • ProductionCapacity: 100 Kilogram/Day
  • Purity: 99%
  • Storage: Store in dry, dark and ventilated plac...
  • Transportation: sea air
  • LimitNum: 1 Kilogram

Superiority

  • ProName: Sex Enhancement Powder Flibanserin cas...
  • CasNo: 167933-07-5
  • Molecular Formula: C20H21F3N4O
  • Appearance: White Or Almost White Crystalline Powd...
  • Application: Bulking cycle
  • DeliveryTime: 4-7days
  • PackAge: 1kg/foil bag or as you requst
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99%
  • Transportation: by express
  • LimitNum: 10 Gram
  • Alias: Flibanserin
  • Molecular formula: C20H21F3N4O
  • Molecular Weight: 390.40
  • Grade: Pharmaceutical Grade

Details

flibanserin

synonyms:3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1h-benzimidazol-2-one

cas no.:167933-07-5

molecular formula:c20h21f3n4o

molecular weight:390.40

purity:99%

grade:pharmaceutical grade

appearance:white powder

grade:pharmaceutical grade

product categories:api

addyi (flibanserin) is a novel, non-hormonal, multifunctional serotonin agonist antagonist (msaa) for the treatment of hypoactive sexual desire disorder in premenopausal wome.

flibanserin, a medical treatment for female hypoactive sexual desire disorder

flibanserin ( addyi ) is a new drug being investigated for the prevention of hsdd in woman. hsdd, is a relatively new term developed to describe hypoactive sexual desire disorder which basically means a woman whose is otherwise healthy has a lacking libido, or a lack of sexual desire. studies show that about 10-20% of women face this problem and some say hsdd outnumbers men with sexual problems. flibanserin is classified as a 5-ht serotonin receptor agonist and a dopamine d4 receptor partial agonist. it is a non-hormonal agent that in essence increases dopamine and noradrenalin while reducing serotonin in the brain. this in return seemingly has a positive effect on a woman's sexual craving who was otherwise lacking in this area. the benefits of it being non-hormonal are that it will not have the problems associated with other hormonal treatments such as a negative altered mood among other issues.

medical uses

flibanserin is used for hypoactive sexual desire disorder among women. those receiving flibanserin report a 0.5 increase compared to placebo in the number of times they had “satisfying sexual events”. in those on flibanserin it rose from 2.8 to 4.5 times a month while women receiving placebo reported also an increase of “satisfying sexual events” from 2.7 to 3.7 times a month. the onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.

the effectiveness of flibanserin was evaluated in three phase 3 clinical trials. each of the three trials had two co-primary endpoints, one for satisfying sexual events (sses) and the other for sexual desire. each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. all three trials showed that flibanserin produced an increase in the number of sses and reduced distress related to sexual desire. the first two trials used an electronic diary to measure sexual desire, and did not find an increase. these two trials also measured sexual desire using the female sexual function index (fsfi) as a secondary endpoint, and an increase was observed using this latter measure.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog